Trodelvy Improves Progression-Free Survival for HR+, HER2- MBC
Trodelvy Slightly Improves Progression-Free Survival for Pre-treated Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer
June 8, 2022
Trodelvy (chemical name: sacituzumab govitecan-hziy) slightly improved progression-free survival in people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer previously treated with hormonal therapy, a CDK4/6 inhibitor, and multiple lines of chemotherapy. Read more...